BERBAGAI PENANDA BIOLOGIS PADA URTIKARIA KRONIK SPONTAN
DOI:
https://doi.org/10.33820/mdvi.v47i4.377Keywords:
biomarker, keaktifan penyakit, respon terapi, urtikaria kronik spontanAbstract
Chronic spontaneous urticaria (CSU) is a mast cell driven skin disorder that is characterized by the development of recurrent itchy wheals for 6 weeks or more due to unknown causes. Diagnosis is purely clinical while assessment of disease activity, its impact on quality of life, as well as treatment efficacy are based on history, physical examination, and the use of questionnaires. However, questionnaires have the disadvantage of being subjective. In the last decade, studies have been focusing on understanding of chronic spontaneous urticarial pathomechanism and identification of potential biomarkers to determine disease activity, clinical course, and treatment efficacy. Some of the biomarkers that have been studied are D-dimer, C reactive protein, interleukin-6, FcεRI, and vitamin D. Biomarkers will then be classified into clinical and molecular biomarkers. With identification of biomarkers that considered to be more objective and reliable, personal approach in evaluating the course of the disease and the most suitable treatment for patients can be achieved.
Downloads
Download data is not yet available.
References
1. Hide M, Takahagi S, Hiragun T. Urticaria and angioedema. Dalam: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, dkk, penyunting. Fitzpatrick’s Dermatology in General Medicine. 9th ed. New York: Mc Graw Hill; 2019. H.684-709.
2. Powell RJ, Leech SC, Till S, Huber PAJ, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema Experimental Allergy. Clin Exp Allergy. 2015;547–65.
3. Zuberbier T, Aberer W, Asero R, dkk. The EAACI/GA2LEN/ EDF/WAO guideline for the definition, classification , diagnosis and management of urticaria. Allergy. 2018;73:1393–414.
4. Angelotti F, Puxeddu I, Petrelli F, Croia C MP. Biomarkers in chronic spontaneous urticaria : current targets and clinical implications. J Asthma Allergy. 2019;12:285–95.
5. Kolkhir P, Andre F, Church M, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2016;47:19–36.
6. Kolkhir P, Altrichter S, Hawro T, Maurer M. CRP is linked to disease activity, impact and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73:940–8.
7. Rosandi R. Korelasi kadar D-dimer dengan derajat keparahan dan lama sakit pasien urtikaria kronik [Tesis]. Jakarta: Fakultas Kedokteran Universitas Indonesia;2014.
8. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting edge: biomarkers for chronic spontaneous urticaria. J Immunol Res. 2018; 2018: 5615109.
9. Ye YM, Jin HJ, Hwang EK. Co -existence of chronic urticaria and metabolic syndrome: clinical implications. Acta Derm Venereol. 2013;93:156-60.
10. Kasperska-Zajac A, Sztyle J, Machura E, Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy. 2011;41:1386-91.
11. Woo YR, Jung KE, Koo DW, Lee JS. Vitamin D as a marker for disease severity in chronic urticaria and its possible role in pathogenesis. Ann Dermatol. 2015;27: 423-30.
12. Asero R, Tedeschi A, Coppola R. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol. 2007;119:705-10.
13. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy. 2008;63:176-80.
14.Takeda T, Sakurai Y, Takahagi S, dkk. Increase of coagulation potential in chronic spontaneous urticaria. Allergy. 2011;66:428-33.
15. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129:1307-13.
16. Magen E, Mishal J, Feldman V, dkk. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010;339:504-8.
17. Grattan CEH. Basophils in chronic urticaria. J Invest Derm Symp P. 2001;6:139-40.
18. Ye YM, Yang EM, Yoo HS, SHin YS, Kim SH, Park HS. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Kor Med Sci. 2014;4:265-71.
19. Sanchez Borges M, Tassinari S, Flores A. Epidemiologic features in patients with antihistamine-resistant chronic urticaria. Rev Alerg Mex. 2015;62:279-86.
20. Huilan Z, Bihua L, Runxiang L, Jiayan L, Luyang L, Zhenjie L. Features of antihistamine-resistant chronic urticaria and chronic urticaria during exacerbation. Indian J Dermatol. 2015;60:323.
21. Asero R. D-dimer: a biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol. 2013;132:983-6.
22. Trinh HKT, Pham DL, Ban GY, Lee HY, Park HS, Ye YM. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016; 171:102-10.
23. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid- Grendelmeier P, Grattan CEH. EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64:1256-68.
24. Yasnowsky K, Dreskin S, Efaw B. Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol. 2006;117:1430-4.
25. Zheng Y, Le K, Wada R. Population PK-PD and exposure- response modeling and simulation to support dose recommendation of Xolair in chronic idiopathic urticaria/chronic [Conference paper]. 2014.
26. Ertas R, Ozyurt K, Ozlu E. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;140:1749-51.
27. Ferrer M, Gimenez-Arnau A, Saldana D. Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis. J Allergy Clin Immunol. 2018;6:1191-7.
28. Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levell parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017;172:40-4.
29. Altrichter S, Hawro T, Hanel K. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatol Venereol. 2016;30:454-5.
30. Asero R. Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:1401-3.
2. Powell RJ, Leech SC, Till S, Huber PAJ, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema Experimental Allergy. Clin Exp Allergy. 2015;547–65.
3. Zuberbier T, Aberer W, Asero R, dkk. The EAACI/GA2LEN/ EDF/WAO guideline for the definition, classification , diagnosis and management of urticaria. Allergy. 2018;73:1393–414.
4. Angelotti F, Puxeddu I, Petrelli F, Croia C MP. Biomarkers in chronic spontaneous urticaria : current targets and clinical implications. J Asthma Allergy. 2019;12:285–95.
5. Kolkhir P, Andre F, Church M, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2016;47:19–36.
6. Kolkhir P, Altrichter S, Hawro T, Maurer M. CRP is linked to disease activity, impact and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73:940–8.
7. Rosandi R. Korelasi kadar D-dimer dengan derajat keparahan dan lama sakit pasien urtikaria kronik [Tesis]. Jakarta: Fakultas Kedokteran Universitas Indonesia;2014.
8. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting edge: biomarkers for chronic spontaneous urticaria. J Immunol Res. 2018; 2018: 5615109.
9. Ye YM, Jin HJ, Hwang EK. Co -existence of chronic urticaria and metabolic syndrome: clinical implications. Acta Derm Venereol. 2013;93:156-60.
10. Kasperska-Zajac A, Sztyle J, Machura E, Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy. 2011;41:1386-91.
11. Woo YR, Jung KE, Koo DW, Lee JS. Vitamin D as a marker for disease severity in chronic urticaria and its possible role in pathogenesis. Ann Dermatol. 2015;27: 423-30.
12. Asero R, Tedeschi A, Coppola R. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol. 2007;119:705-10.
13. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy. 2008;63:176-80.
14.Takeda T, Sakurai Y, Takahagi S, dkk. Increase of coagulation potential in chronic spontaneous urticaria. Allergy. 2011;66:428-33.
15. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129:1307-13.
16. Magen E, Mishal J, Feldman V, dkk. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010;339:504-8.
17. Grattan CEH. Basophils in chronic urticaria. J Invest Derm Symp P. 2001;6:139-40.
18. Ye YM, Yang EM, Yoo HS, SHin YS, Kim SH, Park HS. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Kor Med Sci. 2014;4:265-71.
19. Sanchez Borges M, Tassinari S, Flores A. Epidemiologic features in patients with antihistamine-resistant chronic urticaria. Rev Alerg Mex. 2015;62:279-86.
20. Huilan Z, Bihua L, Runxiang L, Jiayan L, Luyang L, Zhenjie L. Features of antihistamine-resistant chronic urticaria and chronic urticaria during exacerbation. Indian J Dermatol. 2015;60:323.
21. Asero R. D-dimer: a biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol. 2013;132:983-6.
22. Trinh HKT, Pham DL, Ban GY, Lee HY, Park HS, Ye YM. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016; 171:102-10.
23. Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid- Grendelmeier P, Grattan CEH. EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64:1256-68.
24. Yasnowsky K, Dreskin S, Efaw B. Chronic urticaria sera increase basophil CD203c expression. J Allergy Clin Immunol. 2006;117:1430-4.
25. Zheng Y, Le K, Wada R. Population PK-PD and exposure- response modeling and simulation to support dose recommendation of Xolair in chronic idiopathic urticaria/chronic [Conference paper]. 2014.
26. Ertas R, Ozyurt K, Ozlu E. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;140:1749-51.
27. Ferrer M, Gimenez-Arnau A, Saldana D. Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis. J Allergy Clin Immunol. 2018;6:1191-7.
28. Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levell parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017;172:40-4.
29. Altrichter S, Hawro T, Hanel K. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatol Venereol. 2016;30:454-5.
30. Asero R. Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:1401-3.
Downloads
Published
2022-07-12
How to Cite
Bianti, M., Budianti, W. K., & Irawan, Y. (2022). BERBAGAI PENANDA BIOLOGIS PADA URTIKARIA KRONIK SPONTAN. Media Dermato-Venereologica Indonesiana, 47(4), 234–238. https://doi.org/10.33820/mdvi.v47i4.377
Issue
Section
Tinjauan Pustaka
